ETLI:F:F-Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 9.741

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.09 (-0.31%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.21 (-0.41%)

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.28 (+0.05%)

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.06 (-0.40%)

USD 63.18B
VUSA:F Vanguard Funds Public Limited ..

-0.61 (-0.56%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.98 (-0.90%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.80 (-0.33%)

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

+0.06 (+0.77%)

USD 43.12B
0ZC:F Zscaler Inc

+2.50 (+1.39%)

USD 37.92B

ETFs Containing ETLI:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.75% 74% C 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.75% 74% C 61% D-
Trailing 12 Months  
Capital Gain 1.64% 30% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.64% 26% F 40% F
Trailing 5 Years  
Capital Gain 2.66% 36% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.66% 34% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain -1.38% 27% F 37% F
Dividend Return -1.38% 24% F 33% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.88% 69% C- 91% A-
Risk Adjusted Return -13.96% 25% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.